Who are IPTp-sulphadoxine-pyrimethamine plus metronidazole's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/iptp-sulphadoxine-pyrimethamine-plus-metronidazole.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

IPTp-sulphadoxine-pyrimethamine plus metronidazole — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

IPTp-sulphadoxine-pyrimethamine plus metronidazole (IPTp-sulphadoxine-pyrimethamine plus metronidazole) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antifolate antimalarial + nitroimidazole antibiotic. Area: Infectious Disease / Obstetrics.

phase 3 Antifolate antimalarial + nitroimidazole antibiotic Plasmodial dihydrofolate reductase (SP); bacterial/parasitic DNA (metronidazole) Infectious Disease / Obstetrics Small molecule Live · refreshed every 30 min

Target snapshot

IPTp-sulphadoxine-pyrimethamine plus metronidazole (IPTp-sulphadoxine-pyrimethamine plus metronidazole) — London School of Hygiene and Tropical Medicine. This combination therapy prevents malaria and treats bacterial/parasitic infections in pregnant women through antifolate antimalarial activity and broad-spectrum antimicrobial action.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
IPTp-sulphadoxine-pyrimethamine plus metronidazole TARGET	IPTp-sulphadoxine-pyrimethamine plus metronidazole	London School of Hygiene and Tropical Medicine	phase 3	Antifolate antimalarial + nitroimidazole antibiotic	Plasmodial dihydrofolate reductase (SP); bacterial/parasitic DNA (metronidazole)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antifolate antimalarial + nitroimidazole antibiotic class)

London School of Hygiene and Tropical Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IPTp-sulphadoxine-pyrimethamine plus metronidazole — Competitive Intelligence Brief. https://druglandscape.com/ci/iptp-sulphadoxine-pyrimethamine-plus-metronidazole. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab